Half the doctors surveyed said the determination would influence their decision to prescribe potential antibeta-amyloid rivals, too. Those would be Eli Lilly's donanemab, Roche's gantenerumab and Biogen's follow-up monoclonal antibody, lecanemab, which it's developing with Eisai. The CMS will take comments on its decision through Feb. 10. A final Aduhelm coverage verdict is expected in April. Speaking about CMS' comment period, Biogen CEO Vounatsos said on last month's investor call, "we encourage others to make their voice heard so that this final decision expected in April will allow for broader and more equitable access." If the decision goes through in its current form, Biogen thinks Aduhelm may reach just "hundreds" of patients for the foreseeable future, despite the millions affected by Alzheimer's disease, the CEO said. Biogen isn't the only one frustrated by the CMS proposal.